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Superparamagnetic iron oxide nanoparticles (SPIONs) and oxaliplatin (OHP) were in-situ encapsulated
in pectin cross-linked with Ca2þ forming 100–200 nm sized magnetically functionalized pectin
nanocarriers, referred here as MP-OHP nanocarriers. The scanning electron microscopy (SEM) and
transmission electron microscopy (TEM) studies revealed formation of spherical nanostructures. The
magnetic measurements by vibration sample magnetometer (VSM) revealed high saturation magne-
tization (Ms¼45.65 emu/g). The superparamagnetic property of MP-OHP was conﬁrmed from the
blocking temperature (TB) determined from ﬁeld cooled and zero ﬁeld cooled magnetization, measured
by superconducting quantum unit interference device (SQUID) magnetometry. The stability of the
aqueous dispersion of MP-OHP nanocarriers was conﬁrmed from its high zeta potential (30.5 mV).
The drug encapsulation efﬁciency (55.274.8% w/w) and the drug loading content (0.1070.04 wt%) in
MP-OHP nanocarriers were determined from corresponding platinum contents in OHP and MP-OHP
batches measured by inductively coupled plasma mass spectrometry (ICPMS). These nanocarriers
exhibited a sustained release of OHP in phosphate buffer solution maintained at pH 5.5 and 7.4, where
the drug release proﬁle satisﬁed a combination of diffusion and swelling controlled mechanism. The
cytotoxicity effect of MP-OHP nanocarriers was studied on MIA-PaCa-2 (pancreas) cancer cell line,
where the GI50 values were more than 5 mg/mL and it exhibited 10 folds higher cytoxicity than the
equivalent concentration of free drug.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Conventional chemotherapy has limitations due to non-selective
binding of cytotoxic drug leading to biodistribution of the drugs to
various organs in the body. Further, poor pharmacokinetic properties
of these drugs demand repeated drug dosing at its maximum
tolerated dose (MTD) to maintain a desirable drug concentration in
the serum to achieve optimum therapeutic effect [16]. But concen-
trations of these cytotoxic drugs in the serum could exceed the
tolerance level and due to its lack of non-speciﬁc distribution in
human body, these drugs might exhibit severe toxicity to healthy
cells and tissues as well [47]. This has prompted to innovative
therapeutic strategies where the drug is delivered at a targeted
pathological site [1,5]. Such targeted drug delivery would promote
accumulation of active drug molecules at pathological areas [24]. In
this regard, the concept of magnetic targeting by using superpar-
amagnetic iron oxide nanoparticles (SPIONs) encapsulated in biode-
gradable polymers has been receiving tremendous interest [31]. It
was noted that the clinical phase-1 trials on SPIONs loaded polymericll rights reserved.
x: þ91 1332 286202.
gmail.com (R.K. Dutta).nanomaterials were non-toxic [29]. Ideally the magnetic carrier
should be like a core-shell structure where SPIONs and drug
constitute the core while the biodegradable polymer acts as a shell
[48]. Signiﬁcant studies on model drug loaded in magnetically
functionalized polymeric nanoparticulates are reported [3,4,823]. In
this regard, use of biocompatible and biodegradable natural polymers
e.g. chitosan, has shown the potential to improve the therapeutic
index [6]. In addition, reduction of the sizes of these polymeric
magnetic carriers to a few 100 nm is desirable to promote enhanced
permeation and retention (EPR) effect [30] and moreover such small
carriers could be efﬁciently transported through biological pathways
to remote pathological locations by capillary action using external
magnetic ﬁeld. The choice of polysaccharides is usually based on its
efﬁciencies to load sufﬁcient amount of drug and SPIONs, minimum
leakage of drug and SPIONs during transportation, controlled or
predictable drug release at the target site and biodegradability with
either elimination or minimized toxicity of degraded products [2].
There has been considerable development of nanoparticulates
of polysaccharide or protein loaded with model cytotoxic drugs
like 5-ﬂuorouracil, doxorubicin or platinum based compounds
[14,21,34,37]. Due to better anti-tumor activities, polysaccharide
nanocarriers loaded with platinum based drugs, e.g., cis-platin,
oxaliplatin were explored [22,25]. These nanocarriers though
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any targeting ability.
The purpose of this present work was to develop a model oral
nanoscale anticancer drug delivery system targeted to pancreas. The
delivery system is a magnetically functionalized pectin cross linked
with Ca2þ nanostructures containing oxalate(trans-l-1,2-diaminocy-
clohexane) platinum(II), i.e., oxaliplatin, a third generation platinum
based anti-cancer drug. The SPIONs (magnetite nanoparticles) are
encapsulated in these pectin nanostructures to impart magnetic
targeting ability as well as to conﬁne the drug delivery system to
localized areas for sustained drug delivery. We have chosen pectin as
a biodegradable polymer as it is known to be an excellent matrix for
oral administrated colon speciﬁc drug delivery [28,39,45], due to its
resistance to protease and amylase [15] that are active in upper
gastrointestinal (GI) tract. In-spite of excellent drug formulation
properties of pectin, it has not been widely explored for developing
nanocarriers based anti-cancer drug delivery system [46].
In the present study, oxaliplatin was chosen as the anti-cancer
drug due to its better anti-tumor activities with lesser likelihood to
develop drug resistance owing to cyclohexyldiamine group [17].
Furthermore, the oxalato-bidentate ligand contributes to hydrophi-
licity of the drug (water solubility of 6 mg/mL at 20 1C). Due to this it
is more soluble in blood plasma and exhibits better efﬁcacy than the
less hydrophilic cis-platin or carboplatin. Moreover, clinical results
of oxaliplatin are favorable for treating various types of cancers
including the colorectal metastatic pancreatic cancer [20]. Usually,
the efﬁcacy of anticancer drug depends on the ability to target the
drug at tumors, which is cumbersome for colon and pancreas. The
targeting ability of our fabricated pectin nanocarriers loaded with
OHP was induced by incorporating superparamagnetic iron oxide
nanoparticles (SPIONs), preferably magnetite nanoparticles. The
structural, morphological and magnetic properties of fabricated
nanocarrier drug delivery system were characterized by various
techniques. The in vitro drug release from these nanocarriers was
studied at a different pH and its application as a targeted drug
delivery was assayed against cancer cells.2. Materials and methods
2.1. Materials
Fe(NO3)3 9H2O, FeSO4 7H2O, liquid ammonia, anhydrous
Ca(OH)2 of Analytical Grade were procured from Merck, India
and were used without further puriﬁcation. Pectin with 65% to
70% degree of esteriﬁcation was obtained from Hi-Media lab, India.
Oxaliplatin (O9512-5MG) was procured from Sigma Aldrich
(GmbH) Germany. The chemicals for preparing phosphate buffer
solution at pH 5.5 and pH 7.4, comprised di-potassium hydrogen
orthophosphate (K2HSO4), potassium dihydrogen orthophosphate
(KH2PO4), sodium hydroxide and phosphoric acid (H3PO4), were
procured from Merck, India. The acidic pH was maintained by
adding dilute H3PO4. Dialysis membrane made up of regenerated
cellulose with MWCO of about 3500 Da, was procured from Fisher
Scientiﬁc Pittsburgh PA. Millipore water (resistivity of 18.1 MO cm
at 25 1C) was used in all the experiments. All chemicals, reagents
and experimental facilities needed for cell viability studies were
provided by Tata Memorial Centre, Advanced Centre for Treatment
Research and Education in Cancer (ACTREC) Mumbai (India).
2.2. Fabrication of pectin based magnetic nanocarrier drug delivery
system.
5 mg of oxaliplatin (OHP) was mixed with 2.5 mL of Millipore
water to prepare 2.0 mg/mL stock solution of OHP at pH 4. From
this stock solution, 250 mL was mixed with 5 mL of 0.4% w/vpectin solution and was stirred for 1 h at room temperature. To
this solution, 5 mL of a freshly prepared dispersion of magnetite
nanoparticles (MNPs) synthesized by co-precipitation of 2:1 M
ratio of Fe(NO3)3 9 H2O and FeSO4 7 H2O with liquid ammonia
[32] was added after conditioning the MNPs at pH 4. As chloride
ions tend to form an inactive precipitate of 1,2-diaminocyclohex-
ane platinum(II) complex [12], the pH of the reaction medium
was maintained by dil. H3PO4. For the same reason, the pectin
solution was cross-linked by adding 0.8% w/v solution of Ca(OH)2
drop wise in acidic condition (pH4). In this study the composi-
tion of pectin and Ca2þ ions at pH 4 was kept 0.4% and 0.8% w/v,
respectively, as optimized by us earlier [38]. The total volume of
the reaction mixture (15.25 mL) comprising pectin, Ca(OH)2
solution, freshly prepared MNPs and aqueous solution of oxali-
platin was stirred for 6 h at room temperature to allow the
formation of calcium pectinate nanocarriers with MNPs and
OHP encapsulated. This batch of sample will be referred here as
MP-OHP nanocarriers, which were magnetically separated from
the nanostructures of calcium pectinate without MNP encapsula-
tion. The MP-OHP nanocarriers were puriﬁed by washing several
times in phosphate buffer solution for removing loosely adhered
drug and MNPs on the surface of the nanostructures. It may be
remarked that negligible amount of MNPs might remain on the
surface of calcium pectinate nanostructures as demonstrated by
us earlier by X-ray photoelectron spectroscopy [38]. The MP-OHP
nanocarriers were lyophilized for further studies. Similarly, a
batch of calcium pectinate nanostructures were synthesized
where MNPs were encapsulated along with oxaliplatin, and this
batch of sample will be referred to as MP.
2.3. Methodology for drug loading analysis
The as-fabricated MP-OHP dispersion comprised of free dis-
solved drug (y) and drug loaded in MP-OHP nanocarriers (x). If the
initial amount of the drug taken is w, then the drug loaded in MP-
OHP nanocarriers is calculated as x¼wy. The concentration of
free dissolved drug in the dispersion was determined by the bulk
equilibrium reverse dialysis method [27]. The concentration of
the drug was measured by inductively coupled plasma mass
spectrometry (ICPMS). The drug loading content, i.e., the amount
of loaded drug per weight of the MP-OHP nanocarrier (in wt%)
was calculated as (x/t)100, where t¼weight of the fabricated
MP-OHP. The % encapsulation efﬁciency of the drug in the
nanocarrier is given as (x/w)100.
2.4. Characterization
The X-ray diffraction (XRD) measurements of the fabricated
MP-OHP and MNPs were performed with a powder diffractometer
(Bruker AXS D8 Advance) using graphite monochromatized CuKa
radiation source. The morphology of the fabricated MP-OHP batch
was studied by the transmission electron microscopy (TEM)
operated at 200 kV FEI Technai-G2 microscope and by the ﬁeld
emission scanning electron microscopy (beam resolution of 2 nm)
with energy dispersive x-ray analyzer (FESEM-EDAX, FEI-Quanta
200 F) operated at 20 kV. The sample for TEM studies was
prepared by dropping a diluted dispersion of MP-OHP nanocar-
riers on a carbon coated 150 mesh copper grid and dried at room
temperature. Similarly for SEM studies, the diluted dispersion of
MP-OHP was sprayed on a clean glass plate, dried in air and then
coated with ultra-thin layer of Au. Dynamic light scattering (DLS)
experiments were performed by using the Malvern Zetasizer
Nano ZS90 instrument with a 4 mW He–Ne laser (633 nm
wavelength) and a detector at a ﬁxed angle of 1731. The DLS
based size measurements were carried out in triplicate at 25 1C
by transferring about 1 mL of dust free sample solution into
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potentials (x) of the MP-OHP, pectin, OHP, MNP and MP batches
were measured in triplicate at 25 oC by injecting 0.75 mL of dust
free sample solution into disposable folded capillary cells (Mal-
vern). The magnetic properties of the batches of MP-OHP, MP and
MNP were recorded by vibrating sample magnetometer (VSM,
Princeton applied Research Model 155) and by superconducting
quantum unit interference device (SQUID) magnetometer
(MPMSXL, USA). The magnetization measurements using VSM
were recorded from the hysteresis loop ofM–H curve in the range
7 10 kOe at room temperature. For SQUID measurement, a
known amount of lyophilized samples were packed in diamag-
netic capsules and were inserted in a polyethylene straw as a
sample holder. The ﬁeld cooled (FC) and zero ﬁeld cooled (ZFC)
measurements were recorded using SQUID at an applied ﬁeld of
50 Oe by scanning between 5 and 300 K.
2.5. In vitro drug release
The dialysis bag diffusion technique was used to study the
in vitro release of OHP from MP-OHP nanocarriers [41]. Brieﬂy,
the batches of MP-OHP nanocarriers were transferred to a dialysis
bag, referred to as a donor compartment, containing 5 mL of freshly
prepared phosphate buffer solution at pH 5.5 (without enzyme).
This bag with its contents was then transferred to 20 mL of the
buffer solution at pH 5.5 without enzymes (referred as receptor
compartment) and gently stirred at 100 rpm for 40 h at 37.070.1 1C
in an incubator shaker. The choice of pH of 5.5 for the release study
was to simulate mild acidic condition in the vicinity of tumor tissues
[18]. In addition the pH of 5.5–5.7 also simulates that of the
proximal colon for mimicking release of OHP from the fabricated
nanocarriers at colon speciﬁc target [28]. In a similar manner the
release of OHP from MP-OHP nanocarriers was performed in
phosphate buffer solution at pH 7.4, without enzyme for 48 h to
mimic the drug release in blood. About 1.5 mL of an aliquot was
withdrawn from the respective receptor compartments at each
speciﬁed time periods and was replaced with equal volume of fresh
medium to mimic the sink conditions of the human body. The
aliquot was centrifuged at 15000 rpm for 15 min and the super-
natant liquid consisting of released drug was analyzed.
2.6. Methodology for drug analysis
The drug analysis was performed by measuring corresponding
Pt concentration in the drug. Inductively coupled plasma mass
spectrometry (ICPMS, Perkin Elmer Sciex, Elan DRC-e) was used
for measuring Pt concentration, which was of the order of
mg mL1 in the released media. This method is based on ioniza-
tion of analyte by plasma and subsequent determination of ionic
species in terms of mass/charge ratio using the mass spectro-
metry technique. First the analysis of Pt concentration was
calibrated by measuring known standard platinum solutions
(Merck, India) of concentrations of 50, 100, 250, 500 and
750 ng mL1, which corresponded to a linear ﬁt of R2¼0.988
(Fig. S1a, given as supporting material). Next, calibration curve for
estimating drug concentration in phosphate buffer solutions at
pH 5.5 and 7.4 were plotted by measuring Pt concentration by
ICPMS against known drug concentrations, e.g. 200 ng mL1,
350 ng mL1, 500 ng mL1, 750 ng mL1 and 1000 ng mL1.
A linear ﬁt with R2¼0.993 at pH 7.4 (Fig. S1b, given as supporting
material) was obtained. Similarly, a linear correlation with
R2¼0.998 at pH 5.5 was obtained, which indicated the validity
of the method for measuring drug concentration by ICPMS. All the
experiments were performed in triplicate and results are given as
mean7SD (SD¼standard deviation).2.7. Modeling of drug release
The mechanism of drug release from MP-OHP nanocarriers was
studied using Korsemeyer–Peppas equation, given as (Mt/MN)¼
ktn, which can be expressed as Mt/MN100¼(k100) (tn)
[26], where (Mt/MN)100 corresponds to experimentally mea-
sured % cumulative drug release; MN corresponds to 100% drug
release, Mt corresponds to drug release at time (t), ‘k’ is a constant
incorporating structural and geometric characteristics of material
and ‘n’ is the diffusion exponent characteristic of release mechan-
ism. For spheres, the value of no0.43 corresponds to drug release
from the polymer matrix by Fickian diffusion [40]. Similarly, the
value of ‘n’ in the range of 0.43–0.85 indicates diffusion controlled
and swelling controlled drug release. While, n40.85 indicate
swelling controlled drug release, attributed to polymer relaxation
during swelling [44].
2.8. In vitro cell viability
The in vitro cytoxicity study of the batches of MP-OHP
nanocarriers was assayed in MIA-PaCa-2 (pancreas) cancer cell
line by sulforhodamine B (SRB) dye colorimetric assay [42,43].
The cell line was grown in RPMI 1640 medium containing 10%
fetal bovine serum and 2 mM L-glutamine. In the screening
experiment, 5000 cells were inoculated into 96 well microtiter
plates in 100 mL media and incubated at 37 1C, 5% CO2, 95% air and
100% relative humidity for 24 h. Ten microliters of MP-OHP
nanocarriers of concentrations in the range of 1–5 mg/mL was
suspended in phosphate buffer solution at pH 7.4 and incubated
for 48 h. The assay was terminated by addition of cold trichlor-
oacetic acid (TCA). The cells were ﬁxed in situ by the gentle
addition of 50 mL of cold 30% (w/v) TCA and incubated for 60 min
at 4 1C. After discarding the supernatant, the plates were washed
repeatedly with tap water and air dried. To each of the wells, a
50 mL sulforhodamine B solution (SRB), at 0.4% (w/v) in 1% acetic
acid was added, and plates were incubated for 20 min at room
temperature. After staining, the unbound dye was recovered and
the residual dye was removed by washing repeatedly with 1% (w/v)
acetic acid. The plates were air dried and the bound stain was
subsequently eluted with 10 mM trizma base, and the absorbance
was read on a microplate reader at a wavelength of 540 nm.
Percent growth was calculated on a plate-by-plate basis for test
wells relative to control wells, which is expressed as the ratio of
average absorbance of the test well to the average absorbance of
the control wells times 100. These experiments were performed
in triplicate and the cell viability is given as mean7standard
deviation from triplicate analysis. Similarly, 10 mL solution of free
OHP of concentrations e.g., 10, 20, 30, 40 and 50 mg/mL were
treated to the respective cell cultures to assess the anti-prolif-
erative effect of free drug to the cancer cells. As a control, 100 mL
of PBS at pH 7.4 was added to the cells in eight of the wells.
Growth inhibition of 50% (GI50) was calculated from the drug
concentration resulting into 50% reduction in the net protein
increase, which was a measure of SRB staining during the
incubation of cancer cells with drug. The cytotoxicity studies
were performed in the authorized cancer research institute at
Tata Memorial Centre, Advanced Centre for Treatment Research
and Education in Cancer (ACTREC) Mumbai (India).3. Results and discussion
3.1. Fabrication of MP-OHP nanocarriers
The fabrication of spherical nanocarriers of MP-OHP was
conﬁrmed from an array of characterization techniques. The
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spherical shaped MP-OHP nanocarriers with a size distribution
ranging between 100 and 200 nm, in dry condition (Fig. 1, inset).
The MNPs encapsulated in calcium pectinate nanostructures was
evident from the observation of X-ray peaks characteristic to the
compositional elements of MNPs (Fe Ka peak at 6.39 keV and Fe
Kb peak at 7.10 keV) and that of calcium pectinate (Ca Ka peak at
3.63 keV) in the energy dispersive x-ray analysis (EDAX) spec-
trum of a representative nanostructure (Fig. 1). The X-ray peaks of
Pt, corresponding to oxaliplatin, was not detected by EDAX as Pt
content in the MP-OHP nanostructures was below the detection
limits of Pt by EDAX (detection limit was about 500 mg g1).
Further, the morphology of the as-fabricated MP-OHP nano-
structures studied by transmission electron microscopy (TEM)Fig. 1. Scanning electron microscopy of the MP-OHP nanocarriers showing spherical
analysis (EDAX) of a representative nanocarrier marked in the inset revealed co-localiza
calcium pectinate.
Fig. 2. Transmission electron microscopy (TEM) image showing 100 nm spherical MP-
the TEM images correspond to encapsulated polycrystalline magnetite nanoparticles.conﬁrmed the formation of 100–150 nm sized nanostructures
(Fig. 2). The corresponding selected area electron diffraction
(SAED) image showed concentric rings, which were due to the
presence of polycrystalline SPIONs encapsulated in MP-OHP
nanocarriers. The SPIONs encapsulated in MP-OHP were magne-
tite nanoparticles (MNPs), which is revealed from the peaks of the
XRD pattern corresponding to 220, 311, 400, 511 and 440 planes
(Fig. 3). Similar peaks were also detected in the XRD pattern
recorded in the synthesized MNPs. These peaks are characteristic
of the cubic magnetite structure as corroborated with the
reported data in JCPDS (Joint committee on powder diffraction
standards) card number 01-11111 and agreed well with our
previous study of synthesis of MNPs encapsulated in calcium
pectinate nanostructures [38]. The cross-linking of the carboxylicmorphology of about 100–200 nm size (inset) and the energy dispersive X-ray
tion of the characteristic K-x-rays of Fe and Ca as a marker of MNP encapsulated in
OHP nanospheres. The concentric circles observed in the SAED images adjacent to
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Fig. 3. X-ray diffraction pattern of MP-OHP showing all the peaks corresponding
to magnetite nanoparticles (MNP), indicating encapsulation of MNPs in MP-OHP
nanocarriers.
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Fig. 4. (a) Magnetization vs. ﬁeld (M–H) curve of MNPs, MP-OHP and MP batches
measured by VSM at 10 kOe and at room temperature. (b) Superconducting
quantum unit interference device (SQUID) measurement of MP-OHP batch
nanocarriers recorded at 50 Oe showing divergence of magnetization curves
corresponding to zero ﬁeld cooled (ZFC, shown in black) and ﬁeld cooled
(FC, shown in red) plots, indicating superparamagnetism of the MP-OHP.
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substantiated from the measured zeta potential (x) given as mean
value7standard error of mean from triplicate measurements. The x
of pectin was measured as 36.170.6 mV at pH 4, which indicated
negative surface charge due to –COO groups of pectin suitable for
electrostatic interaction with Ca2þ ions, suggested for the egg-box
model for preparation of calcium pectinate structures [13]. Further,
the zeta potential of MNPs at pH¼4 was þ17.670.4 mV and its
encapsulation in pectin nanostructure was likely to be electrostatic in
nature. However, the x value of OHP at pH 4 was measured as
35.270.5 mV and hence its encapsulation in pectin nanostructure
could not be attributable to electrostatic phenomenon. It may be
assumed that the negative surface charge of OHP interacted with the
positive surface charge of MNPs at pH 4, which was then encapsu-
lated in pectin network to form a stable MP-OHP nanostructure. The
stability of the aqueous dispersion of the synthesized MP-OHP in
aqueous medium was corroborated from its measured zeta potential
of 30.570.4 mV. The OHP encapsulation efﬁciency was measured
as 55.274.8% (w/w) of the initial amount of drug treated, and the
loading content of OHP was 0.1070.04 wt% of the fabricated MP-
OHP nanocarriers. From these investigations, it is evident that
oxaliplatin and MNPs were successfully encapsulated in pectin based
nanostructures.
3.2. Magnetic properties of MP-OHP
The magnetic property of the fabricated MP-OHP nanocarrier
was studied by recording magnetization (M) values against
applied magnetic ﬁeld (H) at room temperature using VSM. The
M–H curve of MP-OHP (Fig. 4a) exhibited negligible coercivity and
remanence magnetization, and was similar to that of the as-
synthesized MNPs and MP. This phenomenon was typically due to
superparamagnetism, which is attributable to the magnetite
nanoparticles [9] and is considered to be favorable for targeted
drug delivery [36]. The saturation magnetization (Ms) of MP-OHP
nanocarrier between 710 kOe was measured as 45.65 emu/g. The
Ms value of MP-OHP was similar to that of the MP batch (without
oxaliplatin encapsulation). However, the Ms values of MP-OHP
and MP batches were 20% less than that of the as-synthesized
MNPs (55.69 emu/g). The decrease in the Ms value in MP-OHP
nanocarrier could be attributed due to the formation of magnetic
dead layer by nonmagnetic materials, namely Ca2þ cross linked
pectin at the domain boundary wall of MNPs [19]. The capability
of maneuvering the dispersion of these MP-OHP nanocarriers byexternal magnet was observed (Fig. S2, given as supporting
material). Further, the superparamagnetic behavior of MP-OHP
nanocarrier was conﬁrmed from the SQUID measurement by
recording ﬁeld cooled (FC) and zero ﬁeld cooled (ZFC) magnetiza-
tion at 50 Oe applied ﬁeld in a temperature range between 5 and
300 K (Fig. 4b). The blocking temperature (TB), which is a
characteristic feature of superparamagnetic materials that
depends on the particle size, was determined to be 78.2 K from
the point of divergence of the FC and ZFC plots. Notably, the
blocking temperature value corroborated well with the reported
literature of superparamagnetic iron oxide nanoparticles [32].
3.3. In vitro drug release assay
A time dependent cumulative release of OHP from MP-OHP
nanocarriers was observed in phosphate buffer at pH 5.5 (Fig. 5a)
and at pH 7.4 (Fig. 5b). About 90% of the loaded OHP in MP-OHP was
released in 24 h at pH 5.5. A detailed analysis of drug release
however, revealed 23% release in 0–1 h, and 63% of loaded OHP was
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Fig. 5. (a) Showing in vitro release of OHP from MP-OHP nanocarriers up to 48 h
in phosphate buffer solution kept at pH 5.5. (b) Showing in vitro release of OHP
from MP-OHP nanocarriers up to 48 h in phosphate buffer solution kept at pH 7.4.
Fig. 6. (a) Showing linear ﬁt of in vitro release of OHP up to 7 h from MP-OHP
nanocarriers in phosphate buffer solution at pH 5.5, using Korsemayer–Peppas
equation in log scale. (b) Showing linear ﬁt of in vitro release of OHP up to 7 h
from MP-OHP nanocarriers in phosphate buffer solution at pH 7.4, using
Korsemayer–Peppas equation in log scale.
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OHP at pH 7.4 was analogous to that observed for pH 5.5. About 84%
of the loaded OHP was released in 24 h at pH 7.4 and about 95% was
released in 48 h. Our results were similar to the release patterns of
cis-platin from PLGA-PEG nanoparticles [11]. The detailed analysis
of drug release pattern at pH 7.4 revealed 19% release during the
ﬁrst hour and about 60% of cumulative release was recorded in 7 h.
Notably the rate of drug release was substantially high at pH 5.5 and
at 7.4. It necessitates rapid transport of the MP-OHP nanocarriers to
targeted site to minimize drug leakage at unwanted sites. Due to the
encapsulation of SPIONs, the MP-OHP nanocarriers could be trans-
ported by applying external magnetic ﬁeld and achieve a time
dependent sustained release at a targeted site.
3.4. Drug release mechanism
A plot of cumulative drug release (%) in logarithmic scale, given
as (log Mt/MN)100 against log t, for t¼7 h at pH 5.5 (Fig. 6a) and
7.4 (Fig. 6b), revealed linear ﬁt with R2¼0.9955 and 0.9967
respectively. The factor ‘n’ was determined from the slopes of the
ﬁt as 0.5018 and 0.5886 respectively, for release at pH 5.5 and 7.4.These values of ‘n’ indicated non-Fickian transport, where the drug
release could be considered to be due to combination of diffusion
as well as swelling controlled and corroborated well with literature
reports [40]. The parameter ‘k’ was estimated from the intercepts
of the plots as 0.236 and 0.194 respectively, from the drug release
data in pH 5.5 and 7.4. Notably, the ‘n’ and ‘k’ values determined by
us were in good agreement with polymeric microparticulate based
drug delivery system [44]. The possible swelling effect of pectin
nanocarrier in phosphate buffer solution at pH 5.5 and 7.4 was
indicated in the dynamic light scattering (DLS) measurement. The
average size of MP-OHP at pH 5.5 and at 7.4 were similar and was
measured to be 3307110 (Fig. 7), which was nearly two fold
higher than their corresponding dried samples as measured by
SEM and TEM. It is however not conclusive if the size distribution
of MP-OHP nanocarriers measured by DLS is due to swelling effect
or due to particle aggregation. It may be argued that MP-OHP most
likely swelled in phosphate buffer solution and facilitated drug
release, as supported by the swelling controlled release mechan-
ism. Similar swelling controlled release from calcium pectinate
beads loaded with drug was reported earlier [10]. The observed
swelling can be due to repulsion of increased number of carbox-
ylate groups in pectin (pKa¼2.9–4.1) which are likely to weaken
the calcium pectinate structure [33].
3.5. Cell viability assay of MP-OHP
The cytotoxicity study of the as fabricated MP-OHP nanocarriers
dispersed in pH 7.4 was studied in MIA-PaCa-2 pancreas cancer cell
lines by SRB assay. By treating increasing concentration of 1–5mg/mL
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Fig. 7. Dynamic Light Scattering (DLS) measurement of MP-OHP nanocarriers in aqueous medium at pH 5.5 showing average particulate size of the order of 330 nm due to
swelling effect.
Fig. 8. In vitro cell viability study for MP-OHP nanocarrier, MP and free OHP in
MIA-PaCa-2 (pancreas) cancer cell lines after 48 h interaction by SRB assay.
R.K. Dutta, S. Sahu / Results in Pharma Sciences 2 (2012) 38–4544dispersion of MP-OHP nanocarriers, a systematic decrease in the cell
viability (%) was observed in MIA-PaCa-2 cancer cells (Fig. 8) and the
corresponding GI50 was estimated to be above 5mg/mL. About 40%
inhibition of cancer cell growth was observed for the batch treated
with 5 mg/mL MP-OHP. The cytotoxic behavior of MP-OHP was
compared with free OHP drug of concentration 10–50 mg/mL. The
cell viability pattern for free OHP was similar to that of the MP-OHP
treated batch (Fig. 8), and the GI50 of free OHP was estimated to be
more than 50 mg/mL. Since the batch MP (without drug) did not
exhibit cytotoxicity (Fig. 8), therefore the decrease in cell viability for
MP-OHP nanocarriers in MIA-PaCa-2 cells was deﬁnitely due to
cytotoxic properties of the released OHP drug in the culture medium
at pH 7.4.
From drug loading analysis, it was derived that the drug
loading content in MP-OHP nanocarriers was about 0.1 wt%. In
the case of 95% drug release in 48 h, the corresponding concen-
tration of the released drug would be 10 fold lower than the free
drug, but the extent of cell viabilities for both were nearly similar.
This indicated higher cytotoxicity of MP-OHP nanocarriers
towards pancreas cancer cells. A similar kind of enhancement in
cytotoxicity towards cancer cells has been discussed for doxor-
ubicin loaded in nanoparticles [35]. Compared to free oxaliplatin,
the higher ability of inhibiting the growth of pancreas cancer cells
by MP-OHP could be attributed to higher availability or retention
of MP-OHP nanocarriers with cancer cells. The higher drugavailability could be related to the sustained nature of drug delivery,
as observed at pH 7.4 and also at pH 5.5. However, further studies
on the therapeutic efﬁcacy of our developed MP-OHP nanocarriers
should be carried out on animal models in order to realize its clinical
relevance of magnetically targeted cancer therapy.4. Conclusions
A novel oxaliplatin encapsulated in magnetically functionalized
spherical pectin nanocarriers of 100–200 nm sizes (MP-OHP) has
been successfully fabricated. The encapsulation of magnetite nano-
particles in MP-OHP imparted superparamagnetic property, favor-
able for targeted drug delivery applications. In aqueous medium,
the average size of the nanocarriers was 330 nm, which was
suitable for achieving enhanced permeation and retention (EPR)
in tumors. A reasonably high encapsulation efﬁciency of oxaliplatin
was achieved in these pectin based magnetic nanocarriers. The
drug release from the nanocarriers was sustained at pH 5.5 and
7.4 and attributed to a mixed effect of diffusion and swelling
controlled release mechanism, based on Korsemeyer–Peppas
model. Though the GI50 of MP-OHP in pancreas cancer cell was
above 5 mg/mL, it exhibited 10 folds higher cytotoxicity effect than
the free oxaliplatin, which has been attributed to sustained release
of OHP from MP-OHP nanocarriers. The potential application of
MP-OHP nanocarriers as clinically relevant magnetic nanocarrier
for targeted cancer therapy has to be conﬁrmed from further
studies on animals models.Acknowledgments
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